UFT

DRUG6 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Hokkaido Gastrointestinal Cancer Study Group, The Christie NHS Foundation Trust, Fudan University, Taipei Medical University WanFang Hospital

Conditions

Colon CancerColorectal CancerGastric CancerMetastatic Colorectal CancerNon-small Cell Lung CancerPoststroke/CVA Hemiparesis

Phase 2

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

CompletedNCT01225744

The Christie NHS Foundation TrustMetastatic Colorectal Cancer

Start: 2009-04-30End: 2013-05-31Updated: 2014-06-11

The Maintenance Treatment of UFT in Advanced Gastric Cancer

CompletedNCT02903498

Fudan UniversityGastric Cancer

Start: 2009-08-31End: 2016-09-30Updated: 2016-10-12

Phase 3

Study Evaluating Isovorin in Colon Cancer

CompletedNCT00195585

Wyeth is now a wholly owned subsidiary of PfizerColon Cancer

Start: 2002-10-31End: 2006-02-28Target: 650Updated: 2009-08-13

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

Hokkaido Gastrointestinal Cancer Study GroupColorectal Cancer

Start: 2005-04-30End: 2012-12-31Target: 340Updated: 2010-05-26

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Active, not recruitingNCT06564844

AstraZenecaNon-small Cell Lung Cancer

Start: 2024-10-15End: 2027-06-30Updated: 2026-08-18

Unknown Phase

Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke?

WithdrawnNCT03230370

Taipei Medical University WanFang HospitalPoststroke/CVA Hemiparesis

Start: 2018-12-01End: 2020-05-20Updated: 2019-10-03

Related Papers

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.

2025-09-191 citations